In short
Clinical trials investigating Alendronic Acid are studying its role in people with osteoporosis. These studies look at whether stopping treatment changes fracture risk and measure how well the research works in large patient groups. The main focus is on safety and effectiveness in adults with osteoporosis.
Key points
- Clinical trials investigating Alendronic Acid are focused on osteoporosis. The main study in the source data is a Phase 3 interventional trial with 1400 planned participants. It is a randomized controlled study that looks at the effect of discontinuing alendronate. The main outcome is the number of fragility fractures during the study period. The trial includes adults with osteoporosis and is currently authorised.
Trial overview
The source data include one authorised clinical trial called ALEXIS, which is studying people with osteoporosis.
This study is investigating the effect on fracture risk of discontinuing alendronate, and it is described as a randomized controlled study.
Study design and phase
The trial is an interventional study, which means researchers are assigning the study treatment plan rather than just observing what happens naturally.
It is in Phase 3, which is a later research stage used to test how well a treatment strategy works in a larger group of people.
The planned enrollment is 1400 participants, showing that this is a large study.
Who can participate
The trial targets people with osteoporosis.
The data do not provide more detailed entry rules, such as age limits or other health requirements, so the main known target group is adults with this bone condition.
What is being measured
The primary outcome is the incidence of fragility fractures during the study period.
This means the researchers are counting how often weak-bone fractures happen while people are being followed in the trial.
Because the study looks at fracture risk after stopping alendronate, the main question is whether changing treatment affects the chance of these fractures.
Trial treatments listed in the data
The intervention list includes ALENDRONIC ACID and TETRACYCLINE.
The data show ALENDRONIC ACID as 10 mg oral use, and TETRACYCLINE as 1000 mg oral.
The brief summary specifically says the study investigates the effect on fracture risk of discontinuing alendronate, so the treatment question is about stopping therapy rather than starting a new one.
Why this trial matters
People with osteoporosis have a higher risk of bone fractures, so studies that measure fragility fractures are important for understanding long-term care choices.
This trial may help show whether stopping treatment changes fracture risk in a large, controlled research setting.
Because the study is authorised and in Phase 3, it is one of the more advanced types of clinical research in the source data.